Not suggested during and a pair of months after itraconazole. If coadministration with fentanyl is important, intently observe for respiratory depression and sedation and consider fentanyl dose changes right until stable drug effects are reached.

etravirine will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of fentanyl with CYP3A4 inducers could lead into a minimize in fentanyl plasma concentrations, lack of efficacy or, perhaps, enhancement of the withdrawal syndrome inside a affected individual who may have created physical dependence to fentanyl.

apalutamide will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration of apalutamide, a solid CYP3A4 inducer, with drugs that happen to be CYP3A4 substrates may lead to decrease exposure to those medications.

olanzapine/samidorphan decreases effects of fentanyl by pharmacodynamic antagonism. Contraindicated. Samidorphan elicits opioid antagonistic effects and will increase risk of precipitating acute opioid withdrawal in patients depending on opioids.

Check Carefully (one)omaveloxolone will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

schisandra will raise the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

nevirapine will minimize the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to a lessen in fentanyl plasma concentrations, insufficient efficacy or, maybe, growth of a withdrawal syndrome in the patient who may have designed Actual physical dependence to fentanyl.

Reserve concomitant prescribing of such drugs in patients for whom other treatment options are inadequate. Limit dosages and durations into the minimum demanded. Watch closely for signs of respiratory depression and sedation.

nalbuphine decreases effects of fentanyl by pharmacodynamic antagonism. Keep away from or Use Alternate Drug. Coadministration of mixed agonist/antagonist and partial agonist opioid analgesics may perhaps reduce fentanyl's analgesic effect and possibly precipitate withdrawal symptoms.

إعطاء عبر الأدمة، حقن عضلي، حقن وريدي، عبر الفم، إعطاء تحت اللسان، إعطاء شدقي، إعطاء أنفي

mobocertinib will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fentanyl molecular structure Avoid or Use Alternate Drug. If use is unavoidable, maximize CYP3A4 substrate dosage in accordance with its prescribing information.

lemborexant, fentanyl. Both boosts effects of the other by sedation. Modify Therapy/Keep track of Carefully. Dosage adjustment can be essential if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

fentanyl, cyproheptadine. Possibly increases toxicity with the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may perhaps improve risk for urinary retention and/or intense constipation, which may bring on paralytic ileus.

If coadministration of CYP3A4 inhibitors with fentanyl is essential, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are accomplished.